Summary
Dr Halliday is a Clinical Senior Lecturer and British Heart Foundation Intermediate Fellow at the National Heart and Lung Institute, Imperial College London and Consultant Cardiologist at Royal Brompton and Harefield Hospitals.
His research interests focus on improving the treatment of patients with dilated cardiomyopathy at different stages of disease. He designed and conducted the BHF funded TRED-HF trial, was first author of the primary publication in The Lancet and presented the results at the Late Breaking Clinical Trial Sessions at the American Heart Association, 2018. More recently he has received further BHF funding to perform a follow-on trial in patients with recovered DCM (TRED-HF-2) as well as a trial of a novel antioxidant (MitoQ) in patients with persistent DCM, as part of a prestigious BHF Intermediate Fellowship.
He completed his undergraduate training at University of Edinburgh and was awarded the Murdoch Brown Silver Medal for Medicine, before moving to London to continue his clinical training at Royal Brompton and Harefield Hospitals and St George’s Hospital. He was awarded his PhD in 2018, along with the NHLI Prize for the Best Thesis. He has won national and international young investigator awards for his research from the British Society of Heart Failure, the European Society of Cardiology Heart Failure Association and the American College of Cardiology. He was also awarded a grant from the European Society of Cardiology to complete a part-time MSc in Clinical Trials at the Nuffield Department of Public Health, University of Oxford.
He is on the editorial board of the European Heart Journal and Circulation Cardiovascular Imaging and sits on the British Society of Heart Failure Research Committee as well as the Clinical Research Oversight Committee within the Trust. He is an academic tutor for Imperial medical students and module lead on the cardiovascular intercalated BSc programme.
Publications
Journals
Hammersley DJ, Mukhopadhyay S, Chen X, et al., 2024, Comparative prognostic importance of measures of left atrial structure and function in non-ischaemic dilated cardiomyopathy., Eur Heart J Cardiovasc Imaging
Owen R, Buchan R, Frenneaux M, et al., 2024, Sex differences in the clinical presentation and natural history of dilated cardiomyopathy, Jacc: Heart Failure, Vol:12, ISSN:2213-1787, Pages:352-363
Jones RE, Hammersley DJ, Zheng S, et al., 2024, Assessing the association between genetic and phenotypic features of dilated cardiomyopathy and outcome in patients with coronary artery disease, European Journal of Heart Failure, Vol:26, ISSN:1388-9842, Pages:46-55
Curran L, Simoes Monteiro de Marvao A, Inglese P, et al., 2023, Genotype-phenotype taxonomy of hypertrophic cardiomyopathy, Circulation: Genomic and Precision Medicine, Vol:16, ISSN:2574-8300, Pages:559-570
Kasiakogias A, Ragavan A, Halliday BP, 2023, Your Heart Function Has Normalized-What Next After TRED-HF?, Curr Heart Fail Rep, Vol:20, Pages:542-554